Linda Evangelista CoolSculpting Photos and the Lawsuit
Linda Evangelista CoolSculpting photos show the supermodel before and after a CoolMini treatment that led to paradoxical adipose hyperplasia (PAH). In 2022, a New York jury awarded Evangelista $85 million against CoolSculpting maker Zeltiq Aesthetics and its parent company Allergan Aesthetics, finding that the device caused severe, disfiguring fat loss and asymmetry. The case centered on whether the company adequately warned about rare but serious side effects documented in clinical data and post-market reports. The trial included expert testimony on cryolipolysis mechanisms and imaging evidence from the procedure. Evangelista's legal team cited internal documents showing the company was aware of PAH risks yet did not update labeling or patient consent forms. The verdict is among the largest in U.S. cosmetic device litigation history and has drawn attention from regulatory bodies and industry analysts. The ruling followed a similar 2021 case in which a patient received a $24 million award over CoolSculpting injuries, signaling a trend of rising liability exposure for manufacturers. More background on the case is available in the Forbes analysis of the CoolSculpting verdict.
The Linda Evangelista CoolSculpting photos were introduced as demonstrative evidence to illustrate the asymmetry and contour irregularities caused by PAH. The images were compared with pre-treatment photographs and expert radiologist assessments to show the localized fat hypertrophy that developed months after the procedure. The defense argued that PAH is a known but rare complication and that the photos did not prove a design defect. The jury found otherwise, concluding that the marketing materials misrepresented the safety profile of the CoolMini applicator. The case also highlighted how before-and-after imagery is used in both advertising and litigation to shape perceptions of cosmetic outcomes. The verdict has prompted calls for standardized risk disclosure in cryolipolysis marketing and informed consent documents. The CoolSculpting system works by freezing fat cells, which are then processed and eliminated by the body over weeks, but the FDA has received reports of unexpected fat growth in treated areas. The FDA's MAUDE database tracks adverse event reports tied to cryolipolysis devices, including PAH cases that mirror Evangelista's experience.
CoolSculpting Technology, Zeltiq, and Allergan
CoolSculpting is a noninvasive fat reduction procedure that uses controlled cooling to target and destroy fat cells without surgery. The technology was developed by Zeltiq Aesthetics, which received FDA clearance for the CoolMini applicator in 2017 to treat submental and small area fat deposits. Zeltiq was acquired by Allergan in 2017 for $2.475 billion, and the combined entity continued to market CoolSculpting globally as a leading non-surgical body contouring option. The procedure is performed in outpatient clinics and medspas, with typical sessions lasting 35 to 60 minutes per area. CoolSculpting's parent company, now part of AbbVie after the 2020 Allergan acquisition, reported strong revenue growth from the CoolSculpting franchise, which became a key driver of Allergan's aesthetics division. The company's 2022 annual report and investor presentations highlighted CoolSculpting as a high-margin product line with expanding international adoption. The device uses a vacuum and cooling panels to lower tissue temperature to a point where fat cells crystallize and die, while surrounding skin and nerves remain protected. The process, known as cryolipolysis, was first cleared by the FDA for the flank area in 2010 and later expanded to additional body zones. Detailed technical and regulatory information on cryolipolysis devices can be found